Amgen licenses AMG 634, an investigational treatment for TB and leprosy, to Medicines Development for Global Health

THOUSAND OAKS, Calif. and MELBOURNE, Australia, Dec. 22, 2020 -- Amgen (NASDAQ:AMGN) and Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical company, today announced that the companies have entered into a license agreement for AMG 634, a phosphodiesterase type 4 (PDE4) inhibitor being investigated for the treatment of tuberculosis (TB) and erythema nodosum leprosum (ENL), an inflammatory cutaneous and systemic complication of leprosy. The compound is in Phase 2 development with studies led by the Aurum Institute NPC (TB study) and The Leprosy Mission Nepal (ENL study). Amgen had acquired AMG 634 (formerly CC-11050) as part of its acquisition of Otezla^® (apremilast) from Celgene in 2019. Under the terms of the agreement, MDGH will assume full responsibility for the further development and commercialization of AMG 634.